The safety and performance of the Omnipod® hybrid closed-loop (HCL) personalized model predictive control algorithm was assessed in children with type 1 diabetes (T1D) using an investigational device over 5 days in a supervised hotel setting under free-living conditions. Eligible participants were aged 6-11.9 y with A1C <10.0% using CSII or MDI. A 7-day open-loop (OL) phase of standard therapy (CSII/MDI) plus CGM use at home preceded the 96 h HCL phase. Meals during HCL were unrestricted, with boluses administered per usual routine. Moderate-intensity exercise was performed for ≥30 min/d. An adaptive approach was used to update participant parameters after the first 48 h of HCL. Fifteen participants (MDI n=3) were (mean ± SD): age 9.9 ± 1.0 y, diabetes duration 5.2 ± 2.0 y, A1C 8.0 ± 0.9% and TDD 0.84 ± 0.13 U/kg. Glycemic outcomes are reported in the table. The percentage of time 70-180 mg/dL was 14.3% higher during HCL compared to OL overall (HCL 69.2 ± 13.5 vs. OL 54.9 ± 12.8) and 20.4% higher overnight (HCL 73.8 ± 19.3 vs. OL 53.4 ± 18.8). A concomitant reduction in the percentage of time <70 mg/dL occurred during HCL vs. OL overall (HCL 2.2 ± 1.9 vs. OL 2.9 ± 2.4) and overnight (HCL 1.0 ± 1.9 vs. OL 2.6 ± 2.5). The Omnipod HCL system was safe and performed well over 5 days of use in children with T1D under free-living conditions with unrestricted meals and moderate-intensity exercise.

Glycemic outcomes during hybrid closed-loop (HCL) and open-loop (OL) phases

Glycemic outcomes HCL Overall OL Overall HCL Night (23:00 - 06:59) OL Night (23:00 - 06:59) 
Mean glucose (mg/dL) 156.3 ± 22.1 177.5 ± 28.5 154.8 ± 29.0 177.6 ± 35.2 
Percent time <54 mg/dL (%) 0.3 ± 0.4 0.6 ± 0.6 0.1 ± 0.4 0.8 ± 1.1 
Percent time <70 mg/dL (%) 2.2 ± 1.9 2.9 ± 2.4 1.0 ± 1.9 2.6 ± 2.5 
Percent time 70-140 mg/dL (%) 47.1 ± 12.3 34.5 ± 13.4 52.5 ± 18.4 32.7 ± 16.7 
Percent time 70-180 mg/dL (%) 69.2 ± 13.5 54.9 ± 12.8 73.8 ± 19.3 53.4 ± 18.8 
Percent time >180 mg/dL (%) 28.7 ± 14.1 42.2 ± 14.7 25.2 ± 19.7 44.0 ± 20.8 
Percent time ≥250 mg/dL (%) 8.6 ± 8.8 17.5 ± 11.4 8.6 ± 11.7 16.5 ± 15.0 
Glycemic outcomes HCL Overall OL Overall HCL Night (23:00 - 06:59) OL Night (23:00 - 06:59) 
Mean glucose (mg/dL) 156.3 ± 22.1 177.5 ± 28.5 154.8 ± 29.0 177.6 ± 35.2 
Percent time <54 mg/dL (%) 0.3 ± 0.4 0.6 ± 0.6 0.1 ± 0.4 0.8 ± 1.1 
Percent time <70 mg/dL (%) 2.2 ± 1.9 2.9 ± 2.4 1.0 ± 1.9 2.6 ± 2.5 
Percent time 70-140 mg/dL (%) 47.1 ± 12.3 34.5 ± 13.4 52.5 ± 18.4 32.7 ± 16.7 
Percent time 70-180 mg/dL (%) 69.2 ± 13.5 54.9 ± 12.8 73.8 ± 19.3 53.4 ± 18.8 
Percent time >180 mg/dL (%) 28.7 ± 14.1 42.2 ± 14.7 25.2 ± 19.7 44.0 ± 20.8 
Percent time ≥250 mg/dL (%) 8.6 ± 8.8 17.5 ± 11.4 8.6 ± 11.7 16.5 ± 15.0 

Disclosure

J. Sherr: Consultant; Self; Medtronic MiniMed, Inc.. Advisory Panel; Self; Insulet Corporation, Eli Lilly and Company, Bigfoot Biomedical. G.P. Forlenza: Advisory Panel; Self; Dexcom, Inc.. Research Support; Self; Medtronic, Tandem Diabetes Care, Inc., Insulet Corporation, Dexcom, Inc., Novo Nordisk Inc., Bigfoot Biomedical. B. Buckingham: Advisory Panel; Self; Novo Nordisk Inc., ConvaTec Inc.. Research Support; Self; Medtronic, Insulet Corporation, Dexcom, Inc., Tandem Diabetes Care, Inc.. Consultant; Self; Tandem Diabetes Care, Inc., Becton, Dickinson and Company. T.A. Peyser: Consultant; Self; Insulet Corporation, Dexcom, Inc.. Employee; Self; ModeAGC. Consultant; Self; Biolinq. J. Lee: Employee; Self; Insulet Corporation. J.B. OConnor: None. B. Dumais: Employee; Self; Insulet Corporation. L.M. Huyett: Employee; Self; Insulet Corporation. J.E. Layne: Employee; Self; Insulet Corporation. T.T. Ly: Employee; Self; Insulet Corporation.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.